Humira vs Taltz — patent estate comparison

Side-by-side. 2 estates compared across 0 active patents and $0.0B combined annual revenue.

Drug
Humira
Humira
Taltz
Taltz
Originator
Sohag University
Yale University
Annual revenue
—
—
Active patents
0
0
Avg vulnerability
—
—
Ironclad (<25)
0
0
Vulnerable (≥70)
0
0
Earliest cliff
—
—
Latest expiry
—
—
Cliff (next 15y)

No expiries next 15y

No expiries next 15y

Top claim types
Strongest defences

—

—

Most vulnerable

—

—

Try other comparisons

keytruda vs opdivo vs tecentriqhumira vs enbrel vs remicadeozempic vs mounjaro vs wegovyimbruvica vs calquence vs brukinsa

Want AI commentary on this comparison? Run the AI Patent Landscape Report on the drug class.